Status In progress
Decision Selected
Process HST
ID number 856

Project Team

Project lead Joanne Ekeledo

Email enquiries


Companies sponsors CSL Behring (human alpha1-proteinase inhibitor)
Others Department of Health & Social Care
  NHS England
  Specialised Respiratory Clinical Reference Group (CRG)
Patient carer groups Alpha-1 UK Support Group
Professional groups British Thoracic Society
  UK Clinical Pharmacy Association
Comparator companies GlaxoSmithKline (beclomethasone, fluticasone, salbutamol, salmeterol, seretide, theophylline)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups University of Birmingham COPD and alpha-one anti-trypsin Deficiency Research Group


Key events during the development of the guidance:

Date Update
13 May 2021 Further to recent discussions between NICE and the company, CSL Behring UK. The company have requested a pause whilst next steps are considered for this HST evaluation. We will now pause development of this HST evaluation. At this stage, we are unable to provide alternative timelines as to when the HST evaluation will continue. We will provide a further update in due course.
13 December 2019 - 09 January 2020 Evaluation consultation: 2
07 November 2019 Following the Highly Specialised Evaluation committee discussion held on Thursday 11 April 2019. Draft guidance documentation will be released to consultees and commentators during week commencing 18 November 2019. Draft guidance is expected to publish on the NICE website week commencing 25 November 2019.
11 April 2019 Committee meeting: 2
19 November 2018 The second committee meeting has been rescheduled to 11 April 2018 to allow for attendance of key clinical experts.
18 October 2018 The forthcoming committee meeting to discuss human alpha1-proteinase inhibitor for treating emphysema on Wednesday 24 October 2018 has been rearranged. This is to enable the company to prepare and submit additional information for consideration by the HST committee. Human alpha1-proteinase inhibitor for treating emphysema will be now considered by committee on Thursday 14 March 2019.
26 September 2018 - 17 October 2018 Evaluation consultation
23 August 2018 Committee meeting: 1
26 March 2018 Invitation to participate
21 February 2018 - 21 March 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
21 February 2018 In progress. In progress

For further information on our processes and methods, please see our CHTE processes and methods manual